XRAY
DENTSPLY SIRONA Inc.
XRAY lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to hold roughly steady, though they disagree widely on how much.
XRAY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
XRAY's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
XRAY PE Valuation
XRAY has no meaningful PE right now: it lost money over the past year.
XRAY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect XRAY's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
XRAY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.26 | — |
| Q3 2026 | -$0.62 | +$3.73 |
| Q2 2026 | -$2.75 | +$1.92 |
| Q1 2026 | -$3.15 | +$1.32 |
| Q4 2025 | -$3.00 | +$1.48 |
| Q3 2025 | -$4.35 | -$2.28 |
| Q2 2025 | -$4.67 | -$3.81 |
| Q1 2025 | -$4.47 | -$4.03 |
| Q4 2024 | -$4.48 | -$3.86 |
XRAY is still losing money, but far less than before: $0.62 per share over the past year, against $4.82 at its worst in early 2023.
XRAY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $836M | -7.5% |
| Q2 2026 | $898M | -4.1% |
| Q1 2026 | $880M | +0.1% |
| Q4 2025 | $961M | +6.2% |
| Q3 2025 | $904M | -4.9% |
| Q2 2025 | $936M | -4.9% |
| Q1 2025 | $879M | -7.8% |
| Q4 2024 | $905M | -11% |
XRAY's revenue fell from its 2019 peak and has held roughly level since: $836M last quarter, down 7.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.4% | +29 points |
| Q2 2026 | 9.1% | +23 points |
| Q1 2026 | -4% | -11 points |
| Q4 2025 | -14% | +42 points |
| Q3 2025 | -24% | +25 points |
| Q2 2025 | -14% | -19 points |
| Q1 2025 | 7.2% | +2.8 points |
| Q4 2024 | -56% | -64 points |
XRAY's operating margin was 4.4% last quarter, up 29 points from the same quarter a year ago.
XRAY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $0 | -100% |
| Q2 2026 | $55M | +244% |
| Q1 2026 | -$12M | $0 |
| Q4 2025 | $60M | +67% |
| Q3 2025 | $40M | -59% |
| Q2 2025 | $16M | -90% |
| Q1 2025 | -$12M | -$3M |
| Q4 2024 | $36M | -70% |
XRAY still generates free cash flow, though less than at its 2019 peak: $103M over the past year.
XRAY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -1.3M shares |
| 1 year | -0.2% | -300K shares |
| 3 years | -5.9% | -12.6M shares |
| 5 years | -9.7% | -21.3M shares |
| Available history | -11% | -25.2M shares |
XRAY has 199M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $13M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $100M |
| Q2 2024 | $150M |
| Q1 2024 | — |
| Q4 2023 | $150M |
XRAY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.1x | High |
| Q2 2026 | 50.9x | High |
| Q3 2024 | 39.2x | High |
| Q2 2024 | 6.6x | High |
| Q1 2024 | 5.9x | High |
| Q4 2023 | 6.9x | High |
| Q3 2023 | 6.9x | High |
| Q2 2022 | 1.9x | Healthy |
XRAY's net debt is about 7.1 years of its operating earnings (EBITDA), up from 5.9 years a year ago.
XRAY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.7 | Neutral |
| Stochastic | 22.9 | Neutral |
XRAY's weekly RSI is 41 (neutral) and its Stochastic is 23 (neutral).
XRAY PE vs Healthcare Sector
| Metric | XRAY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XRAY has no meaningful PE right now: it lost money over the past year.
XRAY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.14 | 1.1% above |
| 20 week MA | $10.7 | 14% below |
| 50 week MA | $11.3 | 18% below |
| 100 week MA | $13.2 | 30% below |
| 200 week MA | $22.7 | 59% below |
XRAY has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 59% below its 200-week average.
XRAY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $56.8 | $51.8 | -8.8% |
| 2021 | $51.8 | $55.4 | +7% |
| 2022 | $55.4 | $31.8 | -43% |
| 2023 | $31.8 | $35.6 | +12% |
| 2024 | $35.6 | $18.9 | -47% |
| 2025 | $18.9 | $11.5 | -39% |
| 2026 YTD | $11.5 | $9.24 | -20% |
XRAY has finished lower in four of the last six years. It's down 20% so far in 2026.